What's breaking now, across thousands of outlets.
Five medical organisations have united in an appeal to the NSW premier to pause the planned expansion of pharmacist prescribing powers on safety grounds.
We haven't written up this one. The Sydney Morning Herald has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
The payments by Merck, Eli Lilly, Novartis and AstraZeneca allegedly helped fund a corruption scheme that kept drug prices high and limited competition across Russia’s public healthcare system.
A study investigating the observed connection between pulmonary hypertension and cognitive decline symptoms has linked brain abnormalities in pulmonary hypertension to the same inflammatory processes…
An Elsevier journal on computer applications in biomedicine has retracted 13 papers — including four by a former editor-in-chief — for suspicious authorship changes and erroneous citations.
Chewy's recurring revenue model and high margins clash with Five Below's explosive growth and valuation appeal, here's which edge matters more for your 2027 portfolio.
Two studies involving investigators at Cedars-Sinai Guerin Children's and the University of Cambridge, U.K., highlight the growing potential of whole-genome sequencing to transform the diagnosis and…
The US Food and Drug Administration on Monday approved a low-cost version of a twice-yearly HIV prevention shot, bringing the breakthrough drug closer to market in low-income countries.
